Skip to main content

Pancreatic Enzyme Therapy Linked to Drop in Pediatric Acute Pancreatitis

Medically reviewed by Carmen Pope, BPharm. Last updated on April 16, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 16, 2024 -- Use of pancreatic enzyme therapy (PERT) is associated with a reduction in the incidence rate of acute pancreatitis (AP) among children with pancreatic sufficient acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP), according to a study published online March 22 in the American Journal of Gastroenterology.

A. Jay Freedman, M.D., from Nationwide Children's Hospital at The Ohio State University College of Medicine in Columbus, and colleagues conducted a retrospective cohort study to examine the impact of PERT among children with pancreatic sufficient ARP or CP. Clinical outcomes were compared for those receiving and not receiving PERT.

The researchers found that 76 percent of the 356 pancreatic sufficient participants had ARP and 17 percent received PERT. During a mean follow-up of 2.1 years, 42 percent of those on PERT did not have a subsequent AP episode. The likelihood of having an AP episode after starting PERT was lower for children with SPINK1 mutation and those with ARP versus CP. The mean AP annual incidence rate decreased from 3.14 to 0.71 after initiation of PERT.

"Our findings not only highlight PERT's role in significantly reducing the incidence of acute pancreatitis episodes among children with recurrent or chronic pancreatitis but also underscore the importance of a tailored treatment approach based on genetic markers," coauthor Matthew Giefer, M.D., from Ochsner Children's Hospital in New Orleans, said in a statement.

Several authors disclosed ties to the pharmaceutical, nutritional, and medical technology industries.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

Evidence-Based Approach Recommended for Acute Pancreatitis Management

MONDAY, March 18, 2024 -- In a clinical guideline issued by the American College of Gastroenterology and published online in the March issue of the American Journal of...

GI Adverse Events Increased With Use of GLP-1 Agonists for Weight Loss

FRIDAY, Oct. 6, 2023 -- Use of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss is associated with increased risks for pancreatitis, gastroparesis, and bowel...

Acute Pancreatitis May Progress to Chronic With Sustained Heavy Alcohol Use

WEDNESDAY, Sept. 20, 2023 -- Many patients with recurrent acute pancreatitis (RAP) and acute pancreatitis (AP) have high lifetime cumulative drinking and heavy daily alcohol use...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.